Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro

Neuroendocrinology

Volumn 97, Issue 2, 2013, Pages 183-192

  Somnay, Yash ^a   Chen, Herbert ^a   Kunnimalaiyaan, Muthusamy ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Carcinoid; Neuroendocrine; Pasireotide; Somatostatin analog; Synergy; Teriflunomide

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CHROMOGRANIN A; MITOGEN ACTIVATED PROTEIN KINASE 3; PASIREOTIDE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); TERIFLUNOMIDE; TRANSCRIPTION FACTOR MASH1; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; RAF PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOID; CELL GROWTH; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL SURVIVAL; CELL VIABILITY; DRUG EFFECT; ENZYME PHOSPHORYLATION; IC50; MTT ASSAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOGRANIN A; CROTONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GASTROINTESTINAL NEOPLASMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PANCREATIC NEOPLASMS; SOMATOSTATIN; TOLUIDINES;

EID: 84876297619     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000341810     Document Type: Article

References (49)

1. Modlin I, Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813-829.
2. Läuffer J, Zhang T, Modlin I: Review article: current status of gastrointestinal carcinoids. Aliment Pharmacol Ther 1999; 13: 271-287.
3. Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C, Hanna S, Poitras P, Rayson D, Reid R, Rivera J, Roy A, Shah A, Sideris L, Siu L, Wong R: Guidelines for the diagnosis and management of carcinoid tumours. 1. The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 2006; 13: 67-76.
4. Oberg K: Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 2009; 16: 72-78.
5. Pasieka J: Carcinoid tumors. Surg Clin North Am 2009; 89: 1123-1137.
6. Cook M, Pinchot S, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H: Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther 2010; 9: 429-437.
7. Jiang S, Kameya T, Asamura H, Umezawa A, Sato Y, Shinada J, Kawakubo Y, Igarashi T, Nagai K, Okayasu I: hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 2004; 17: 222-229.
8. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12(suppl 2):S69-S72.
9. Davis Z, Moertel C, McIlrath D: The malignant carcinoid syndrome. Surg Gynecol Obstet 1973; 137: 637-644.
10. Kunnimalaiyaan M, Chen H: The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 2006; 17: 139-142.
11. Chen H, Biel M, Borges M, Thiagalingam A, Nelkin B, Baylin S, Ball D: Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions. Cell Growth Differ 1997; 8: 677-686.
12. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R, Gullo L: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13: 55-58.
13. Sippel R, Carpenter J, Kunnimalaiyaan M, Lagerholm S, Chen H: Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2003; 285:G245-G254.
14. Modlin I, Pavel M, Kidd M, Gustafsson B: Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188.
15. Culler MD, Oberg K, Arnold R, Krenning EP, Sevilla I, Diaz JA: Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011; 30(suppl 1):9-17.
16. Modlin I, Latich I, Kidd M, Zikusoka M, Eick G: Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006; 4: 526-547.
17. Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, De Bellis A, Renzullo A, Bellastella G, Colao A, Vallone G, Bellastella A, Sinisi A: Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008; 40: 263-271.
18. van der Hoek J, van der Lelij A, Feelders R, de Herder W, Uitterlinden P, Poon K, Boerlin V, Lewis I, Krahnke T, Hofland L, Lamberts S: The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 2005; 63: 176-184.
19. Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I: Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008; 113: 690-700.
20. Patel YC, Srikant CB: Somatostatin receptors. Trends Endocrinol Metab 1997; 8: 398-405.
21. Ben-Shlomo A, Melmed S: Pasireotide - a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 2007; 10: 885-895.
22. Kvols L, Oberg K, Glusman JE, O'dorisio TM, De Herder W, Gao B, Arnold R, Anthony L, The SOM230 Carcinoid Study Group: Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study; in Am Soc Clin Oncol Annu Meet, Atlanta, June 2006.
23. van Hoek M, Hofland L, de Rijke Y, van Nederveen F, de Krijger R, van Koetsveld P, Lamberts S, van der Lely A, de Herder W, Feelders R: Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. J Clin Endocrinol Metab 2009; 94: 428-433.
24. Van Gompel J, Kunnimalaiyaan M, Holen K, Chen H: ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 2005; 4: 910-917.
25. Kappes A, Vaccaro A, Kunnimalaiyaan M, Chen H: ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res 2006; 133: 42-45.
26. Florio T, Thellung S, Arena S, Corsaro A, Bajetto A, Schettini G, Stork P: Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol Paris 2000; 94: 239-250.
27. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 1992; 9: 383-391.
28. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
29. Dhanasekaran N, Heasley L, Johnson G: G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev 1995; 16: 259-270.
30. Greenblatt D, Vaccaro A, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, Chen H: Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007; 12: 942-951.
31. Zhao L, Wientjes M, Au J: Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10: 7994-8004.
32. Chou T, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
33. Cescato R, Loesch K, Waser B, Mäcke H, Rivier J, Reubi J, Schonbrunn A: Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 2010; 24: 240-249.
34. Baumann P, Mandl-Weber S, Völkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R: Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009; 8: 366-375.
35. Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T: The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 2008; 22: 635-638.
36. Miller C, Ellison E: Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am 1998; 7: 863-879.
37. Chen H, Hardacre J, Uzar A, Cameron J, Choti M: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 88-92, discussion 92-93.
38. Schmid H: Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286: 69-74.
39. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho Y, Hu K, Farrall A, Melmed S, Biller B, Group PAS: Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010; 95: 2781-2789.
40. Ravi R, Thiagalingam A, Weber E, Mc- Mahon M, Nelkin B, Mabry M: Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human smallcell lung cancer cells. Am J Respir Cell Mol Biol 1999; 20: 543-549.
41. Gollob J, Wilhelm S, Carter C, Kelley S: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392-406.
42. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett M, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson B, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins G, Bigner D, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho J, Leung S, Yuen S, Weber B, Seigler H, Darrow T, Paterson H, Marais R, Marshall C, Wooster R, Stratton M, Futreal P: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
43. Vaccaro A, Chen H, Kunnimalaiyaan M: In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs 2006; 17: 849-853.
44. Chen H, Kunnimalaiyaan M, Van Gompel J: Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue- 1. Thyroid 2005; 15: 511-521.
45. Sippel R, Carpenter J, Kunnimalaiyaan M, Chen H: The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 2003; 134: 866-871; discussion 871-873.
46. Pinchot S, Adler J, Luo Y, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H: Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg 2009; 197: 313-319.
47. Tallantyre E, Evangelou N, Constantinescu C: Spotlight on teriflunomide. Int MS J 2008; 15: 62-68.
48. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebocontrolled, phase II study. Arthritis Rheum 1995; 38: 1595-1603.
49. Chong A, Huang W, Liu W, Luo J, Shen J, Xu W, Ma L, Blinder L, Xiao F, Xu X, Clardy C, Foster P, Williams J: In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999; 68: 100-109.